Global Medical Cannabis Market Report: Trends, Growth and Size Analysis-Forecast to 2027

$4,450$6,250

According to this report, the global Medical Cannabis Market is expected to register a significant CAGR of 18.14% to surpass USD 33,210.21 million by the end of 2027.

Clear
SKU: MRFR210215 Category: Tag:

Description

Global Medical Cannabis Market– Forecast to 2027

Global Medical Cannabis Market Snapshot

According to this report, the global Medical Cannabis Market is expected to register a significant CAGR of 18.14% to surpass USD 33,210.21 million by the end of 2027. Medical marijuana is also called cannabis that has viable remedial properties. The best thing about this plant is that it is used as an unrefined material by various medication associations to make drugs for various medicinal applications.

The genuine usage of cannabis for clinical reasons is extending because of its compelling advantages. In any case, it shifts across countries due to the movement, proprietorship, advancement, and clinical finishes paperwork for its use. One more driver of the Medical Cannabis Market is the rising prevalence of continuous contaminations and different illnesses.

Clinical Cannabis is ensured and amazing for additional creating signs, for instance, rest issues, pressure, and torture achieved by relentless infections in adults.

The expansion of the Medical Cannabis Market is driven by various elements like augmentation in the usage of cannabis, a rising prevalence of progressing diseases, and considerably more. The growing legitimization of Medical Cannabis in different countries rises to research and improvement of cannabinoids.

Nevertheless, growing unlawful usage of Maryjane is depended upon to check the overall Market Outlook advancement. There are various employments of cannabis in the clinical business, which is driving the Medical Cannabis Market development. In the current decade, the use of cannabis has extended even more immediately diverged from various substances.

There has been a speedy advancement in cannabis use and is simply climbing in made countries like Western Europe, North America, and Australia.

Segment Overview

The global medical cannabis market is classified into Species, Derivatives, Application, End-use, and route of administration.

Based on species, the market is divided into cannabis Indica, Sativa, and crossbreed.

By derivatives segment, the market has been categorized into cannabidiol (CBD), tetrahydrocannabinol (THC), and much more.

In terms of applications, the market has been divided into disease addresses the main classification.

By end-use, the market has been classified into the drug business, innovative work communities, and much more.

Depending on the route of administration, the market has been divided into oral arrangements and cases, smoking, vaporizers, topical, and others.

Regional Analysis

The Medical Cannabis market has been fragmented dependent on geographics, Asia-Pacific, Americas, Europe, the Middle East, and Africa. The Americas is depended upon to be the greatest market inferable from the rising consumption of clinical cannabis and rising per capita clinical consideration utilization.

The market in the Americas has furthermore been stretched out into North America and Latin America, with the North American market divided into the US and Canada. The European Medical Cannabis market has been masterminded in Western Europe and Eastern Europe.

Major Market Players

The major players of the Medical Cannabis market include Canopy Growth, Corporation (Canada), GW Pharmaceuticals PLC (UK), Aurora Cannabis (Canada), Aphria, Inc. (Canada), Maricann Inc. (Canada), Tilray (Canada), Cannabis Sativa Inc. (US), GBSciences Inc. (US), United Cannabis (US), Medical Marijuana, Inc. (US), CanniMed Ltd (Canada), and MediPharm Labs (Canada)

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.

Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Global Cannabis Extract Market to Surge at 18.29% CAGR, which is anticipated to reach USD 37.67 billion by 2030.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 MARKET STRUCTURE

2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING R&D ACTIVITIES AND FINANCIAL SUPPORT BY VARIOUS PRIVATE AND GOVERNMENT ORGANIZATIONS

4.2.2 RISING OCCURRENCE OF CHRONIC DISEASES AND OTHER MEDICAL CONDITIONS

4.2.3 LEGALIZATION OF MEDICAL CANNABIS IN VARIOUS REGIONS

4.3 RESTRAINTS

4.3.1 ADVERSE EFFECTS ASSOCIATED WITH CANNABIS

4.3.2 STRINGENT GOVERNMENT POLICIES RELATED TO CBD OIL

4.4 OPPORTUNITIES

4.4.1 IMPROVING STATUS OF CANNABIS IN ASIAN AND AFRICAN COUNTRIES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 PROCUREMENT OF RAW MATERIALS

5.1.2 R&D

5.1.3 MANUFACTURING

5.1.4 DISTRIBUTION AND SALES

5.1.5 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE MEDICAL CANNABIS MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON DEMAND FOR MEDICAL CANNABIS

5.3.4 IMPACT ON EXISTING REGULATIONS

5.3.5 IMPACT ON RESEARCH

5.3.6 IMPACT ON BUYERS AND SUPPLIERS

6 GLOBAL MEDICAL CANNABIS MARKET, BY PRODUCT TYPE

6.1 OVERVIEW

6.2 SOLIDS

6.3 DISSOLVABLES/POWDERS

6.4 OIL

6.5 OINTMENTS & CREAMS

7 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVE

7.1 OVERVIEW

7.2 CANNABIDIOL

7.3 TETRAHYDROCANNABINOL

8 GLOBAL MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 INHALATION

8.3 ORAL

8.4 TOPICAL

9 GLOBAL MEDICAL CANNABIS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 PAIN MANAGEMENT

9.2.1 NEUROPATHIC PAIN

9.2.2 CANCER

9.2.3 INFLAMMATORY PAIN

9.3 NEUROLOGICAL HEALTH MANAGEMENT

9.3.1 SCLEROSIS

9.3.2 EPILEPSY

9.3.3 ALZHEIMER’S DISEASE

9.3.4 PARKINSON’S DISEASE

9.3.5 OTHERS

9.4 MENTAL HEALTH MANAGEMENT

9.4.1 POST-TRAUMATIC STRESS DISORDER (PTSD)

9.4.2 DEPRESSION

9.4.3 ANXIETY

9.4.4 OTHERS

10 GLOBAL MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITAL PHARMACY

10.3 RETAIL PHARMACY

10.4 ONLINE PHARMACY

11 GLOBAL MEDICAL CANNABIS MARKET, BY REGION

11.1 OVERVIEW

11.2 AMERICAS

11.2.1 NORTH AMERICA

11.2.1.1 US

11.2.1.2 CANADA

11.2.2 LATIN AMERICA

11.3 EUROPE

11.3.1 WESTERN EUROPE

11.3.1.1 GERMANY

11.3.1.2 FRANCE

11.3.1.3 UK

11.3.1.4 ITALY

11.3.1.5 SPAIN

11.3.1.6 REST OF WESTERN EUROPE

11.3.2 EASTERN EUROPE

11.4 ASIA-PACIFIC

11.4.1 JAPAN

11.4.2 AUSTRALIA

11.4.3 SOUTH KOREA

11.4.4 REST OF ASIA-PACIFIC

11.5 MIDDLE EAST & AFRICA

11.5.1 MIDDLE EAST

11.5.2 AFRICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 COMPETITIVE BENCHMARKING

12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MEDICAL CANNABIS MARKET

12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL MEDICAL CANNABIS MARKET

12.5 KEY DEVELOPMENT ANALYSIS

12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL

12.6.2 MERGER/ACQUISITION

12.6.3 PARTNERSHIP/AGREEMENT

12.6.4 EXPANSION

13 COMPANY PROFILES

13.1 CANOPY GROWTH CORPORATION

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 PRODUCTS/SERVICES OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 CANNABIS SATIVA, INC.

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 PRODUCTS/SERVICES OFFERED

13.2.4 KEY DEVELOPMENTS

13.2.5 SWOT ANALYSIS

13.2.6 KEY STRATEGIES

13.3 GW PHARMACEUTICALS PLC

13.3.1 COMPANY OVERVIEW

13.3.2 FINANCIAL OVERVIEW

13.3.3 PRODUCTS/SERVICES OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 SWOT ANALYSIS

13.3.6 KEY STRATEGIES

13.4 EMERALD HEALTH THERAPEUTICS

13.4.1 COMPANY OVERVIEW

13.4.2 FINANCIAL OVERVIEW

13.4.3 PRODUCTS/SERVICES OFFERED

13.4.4 KEY DEVELOPMENTS

13.4.5 SWOT ANALYSIS

13.4.6 KEY STRATEGIES

13.5 TILRAY, INC.

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 PRODUCT OFFERINGS

13.5.4 KEY DEVELOPMENTS

13.5.5 SWOT ANALYSIS

13.5.6 KEY STRATEGIES

13.6 AURORA CANNABIS INC.

13.6.1 COMPANY OVERVIEW

13.6.2 FINANCIAL OVERVIEW

13.6.3 PRODUCTS/SERVICES OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 SWOT ANALYSIS

13.6.6 KEY STRATEGIES

13.7 CARA THERAPEUTICS

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 PRODUCTS/SERVICES OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 SWOT ANALYSIS

13.7.6 KEY STRATEGIES

13.8 MEDICAL MARIJUANA, INC.

13.8.1 COMPANY OVERVIEW

13.8.2 FINANCIAL OVERVIEW

13.8.3 PRODUCTS/SERVICES OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 SWOT ANALYSIS

13.8.6 KEY STRATEGIES

13.9 GB SCIENCES, INC.

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 PRODUCTS/SERVICES OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 SWOT ANALYSIS

13.9.6 KEY STRATEGIES

13.10 CANNDOC

13.10.1 COMPANY OVERVIEW

13.10.2 FINANCIAL OVERVIEW

13.10.3 PRODUCTS/SERVICES OFFERED

13.10.4 KEY DEVELOPMENTS

13.10.5 SWOT ANALYSIS

13.10.6 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES

14.2 RELATED REPORTS